Reston – January 19, 2017 – Cooley advised Cavion on its $26.1 million Series A financing round. Lilly Ventures and Novartis Venture Fund co-led the round, with additional participation from Enso Ventures and other existing investors.
According to Cavion, the funding will support the development of novel treatments for neurological diseases. Later this year, the company plans to conduct a robust proof-of-concept Phase 2 study of its Cav3 inhibitor CX-8998 for the treatment of essential tremor.
“Cavion’s compelling science and its Cav3 modulators offer a unique opportunity to develop effective therapies for patients with medical needs unmet in the neurological field,” said Dr. Sergei Petukhov, partner at Enso Ventures, in a press release issued by Cavion.
Cavion, based in Charlottesville, Virginia, is a privately held, clinical stage biotechnology company creating therapies for the treatment of neurological and oncologic diseases.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.